Pages that link to "Template:ReferenceData"

The following pages link to Template:ReferenceData:

Displaying 50 items.

• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 63 Paragraph 2 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 63 Paragraph 3 – 5 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 63 Paragraph 6 – 7 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 59 Paragraph 1 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 59 Paragraph 2 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 59 Paragraph 3 – 5 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 59 Paragraph 6 – 7 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 96 Nr. 10, 11, 21 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 28 Absatz 1 – 2 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 28 Absatz 3 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 28 Absatz 4 – 6 (transclusion) (← links)
• Reference:DEU Gemeinsame Empfehlungen - zur Anzeige von Anwendungsbeobachtungen und nichtinterventionellen Unbedenklichkeits-studien 15-Dec-2022 2.7.4 (transclusion) (← links)
• Reference:DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 1 1.2 (transclusion) (← links)
• Reference:DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 5 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 3-001 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (g) (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.102 (e) (1) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (p) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (k)-002 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (l) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.20 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.22 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.23 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.24 (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.25 (a) - (b) (transclusion) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.27 (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.116 (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.117 (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (5) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (8) (transclusion) (← links)
• Reference:USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Verification (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Introduction (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Advertising-001 (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 III. (transclusion) (← links)
• Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 IV. (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.9.1 (transclusion) (← links)
• Reference:EU Regulation (EU) 2016/679 (GDPR) 04-May-2016 Article 9 Paragraph 1 (transclusion) (← links)
• Reference:EU Regulation (EU) 2016/679 (GDPR) 04-May-2016 Article 9 Paragraph 2 (transclusion) (← links)
• Reference:EU Regulation (EU) 2016/679 (GDPR) 04-May-2016 Article 6 Paragraph 1 (transclusion) (← links)
• Reference:DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 4 (transclusion) (← links)
• Reference:GBR Medicines and Medical Devices Act 2021 21-Feb-2021 Chapter 2 Article 8 (transclusion) (← links)
• Reference:GBR UK GDPR - United Kingdom General Data Protection Regulation 31-Dec-2020 Article 9 Paragraph 1 (transclusion) (← links)
• Reference:GBR UK GDPR - United Kingdom General Data Protection Regulation 31-Dec-2020 Article 9 Paragraph 2 (transclusion) (← links)
• Reference:GBR UK GDPR - United Kingdom General Data Protection Regulation 31-Dec-2020 Article 6 Paragraph 1 (transclusion) (← links)
• Reference:GBR Data Protection Act 2018 06-Jun-2022 Article 2 (transclusion) (← links)
• Reference:GBR Data Protection Act 2018 06-Jun-2022 Schedule 10 (transclusion) (← links)
• Reference:USA 45 CFR Part 160 09-Apr-2025 § 164.508 (transclusion) (← links)
• Reference:USA 45 CFR Part 160 09-Apr-2025 § 164.512 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Vulnerable Participants (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.8.9 (transclusion) (← links)